COSM vs HKPD
Cosmos Health Inc. and Cellyan Biotechnology Co. Ltd., side by side — 3 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | COSM | HKPD |
|---|---|---|
| Revenue | $65.3M | $20.3M |
| Net income | $-19.1M | $-27,056 |
| Gross margin | 12.1% | 11.9% |
| Net margin | −29.3% | −0.1% |
| Return on equity | −89.1% | −0.6% |
| Diluted EPS | −$0.63 | −$0.00 |
| Dividend / share | — | — |
| Payout ratio | — | — |
| Free cash flow | $-8.5M | $499,298 |
| Equity | $18.4M | $5.0M |
| Net debt / equity | 0.17× | 0.23× |
| Current ratio | 1.00× | 2.99× |
| Revenue CAGR 5y | 3.3% | — |
| Profit CAGR 5y | — | — |
COSM bills 3.2× the revenue of HKPD, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
3 years side by side
| Fiscal year | COSM | HKPD |
|---|---|---|
| FY2024 | $54.4M | $20.3M |
| FY2023 | $53.4M | $16.7M |
| FY2022 | $50.3M | $12.6M |
Net income by year
Bottom line
| Fiscal year | COSM | HKPD |
|---|---|---|
| FY2024 | $-16.2M | $-27,056 |
| FY2023 | $-18.5M | $1.3M |
| FY2022 | $-13.8M | $998,196 |
Advertisement
AdSense · Rectangle 336×280